| 证券代码：600521 | 证券简称：华海药业 | 公告编号：临 | 2024-051 | 号 | | --- | --- | --- | --- | --- | | 债券代码：110076 | 债券简称：华海转债 | | | | 浙江华海药业股份有限公司 关于向子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 一、 担保情况概述 （一）本次担保基本情况 公司分别于 2023 年 4 月 27 日、2023 年 5 月 19 日召开第八届董事会第一次 会议、2022 年年度股东大会，会议均审议通过了《关于公司 2023 年度向银行申 请综合授信额度及提供担保的议案》，其中股东大会同意为公司及下属全资子公 司、参股子公司向银行申请授信额度提供合计不超过 9.344 亿元（最终以实际发 生额为准）的资产抵押及信用担保（含公司为华海制药科技向银行申请授信额度 提供不超过 8 亿元的信用担保）。 公司股东大会授权公司董事会（或董事会授权人士）在上述综合授信额度及 担保额度内全权办理相关 ...

浙江华海药业股份有限公司 关于召开 2023 年年度股东大会的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 浙江华海药业股份有限公司（以下简称"公司"）于2024年4月26日召开第 八届董事会第二次会议，会议审议通过了《关于提议召开2023年年度股东大会 的议案》，公司将于2024年5月21日召开2023年年度股东大会，并已于2024年4 月30日在中国证券报、上海证券报、证券时报、证券日报和上海证券交易所网 站www.sse.com.cn上刊登了《浙江华海药业股份有限公司关于召开2023年年度 股东大会的通知》。为进一步保护投资者的合法权益，为公司股东行使股东大 会表决权提供便利，现将有关事项再次提示如下： 证券代码：600521 证券简称：华海药业 公告编号：临 2024-052 号 债券代码：110076 债券简称：华海转债 一、 召开会议的基本情况 (一) 股东大会类型和届次 2023 年年度股东大会 1 股东大会召开日期：2024年5月21日 本次股东大会采用的网络投票系统：上海证券交易 ...

浙江华海药业股份有限公司 股东大会会议议案 浙江华海药业股份有限公司 2023 年年度股东大会资料 股票简称：华海药业 股票代码：600521 中国·浙江·临海 二零二四年五月二十一日 浙江华海药业股份有限公司 股东大会会议议案 浙江华海药业股份有限公司 2023 年年度股东大会会议议程 时间：2024 年 5 月 21 日下午 14 点 30 分 地点：浙江省临海市汛桥镇浙江华海药业股份有限公司行政楼高级报告厅 会议议程 一、与会者签到 二、大会开始，主持人讲话 三、审议议案 1、审议《公司 2023 年度董事会工作报告》； 2、审议《公司 2023 年度监事会工作报告》； 3、审议《公司 2023 年度财务决算报告》； 10、审议《关于修订公司章程部分条款的议案》； 11、审议《关于修订<浙江华海药业股份有限公司董事会议事规则>的议案》； 12、审议《关于修订<浙江华海药业股份有限公司独立董事工作制度>的议 案》； 13、审议《关于制定<浙江华海药业股份有限公司会计师事务所选聘制度> 的议案》； 14、审议《关于制定<浙江华海药业股份有限公司期货和衍生品交易管理制 度>的议案》； 4、审议《公司 2023 ...

证券代码：600521 证券简称：华海药业 公告编号：临 2024-050号 债券代码：110076 债券简称：华海转债 浙江华海药业股份有限公司 关于举办投资者接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示：  会议召开时间：2024年5月21日上午 9:30—12:30；  会议召开地点：浙江省临海市汛桥镇浙江华海药业股份有限公司；  会议召开方式：现场召开。 为进一步提高公司治理水平，加强投资者关系管理，增进公司与广大投资者的 沟通和交流，浙江华海药业股份有限公司（以下简称“公司”）定于 2024年5月21 日上午举行投资者接待日活动，届时将针对公司的经营情况、发展战略、公司治理 等投资者关心的问题与广大投资者进行现场的沟通和交流，同时广泛听取投资者的 意见和建议。本次投资者接待日活动具体情况如下： 一、活动召开的时间、地点及方式 活动召开时间：2024年5月21日上午9:30—12:30； ...

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 2024-049 | 号 | | --- | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | | 浙江华海药业股份有限公司 关于子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江华海药业股份有限公司（以下简称"公司"）下属控股子公司长兴制药股 份有限公司（以下简称"长兴制药"）于近日收到国家药品监督管理局（以下简称 "国家药监局"）核准签发的盐酸托莫西汀口服溶液的《药品注册证书》，现将相关 情况公告如下： 一、药品的基本情况 药品名称：盐酸托莫西汀口服溶液 规格：0.4%（100ml：0.4g）（按 C₁₇H₂₁NO 计） 申请事项：药品注册（境内生产） 注册分类：化学药品 4 类 申请人：长兴制药股份有限公司 药品批准文号：国药准字 H20243642 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符 合药品注册的有关要求，批准注册 ...

债券简称：华海转债 债券代码：110076 股票简称：华海药业 股票代码：600521 公告编号：临 2024-047 号 （二）本次增持计划实施前，陈保华先生合计持有公司股份 365,697,935 股，占 公司总股本的比例为 24.67%； （三）增持主体陈保华先生在本次增持计划公告披露前十二个月内无已披露的增 持计划，且在该增持计划公告披露前六个月内不存在减持公司股份的情况。 浙江华海药业股份有限公司 关于控股股东增持公司股份计划实施结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： ● 浙江华海药业股份有限公司（以下简称"公司"）于 2023 年 10 月 31 日披露了 《浙江华海药业股份有限公司关于控股股东增持公司股份计划公告》（公告编号：临 2023-109 号），基于对公司未来发展前景的信心及长期投资价值的认可，公司控股股 东及实际控制人陈保华先生计划自增持计划披露之日起 6 个月内，拟通过上海证券交 易所系统集中竞价交易方式增持公司股份，增持金额不低于人民币 2,000 万元，不 ...

| 证券代码：600521 | 证券简称：华海药业 | 公告编号：临 | 2024-048 | 号 | | --- | --- | --- | --- | --- | | 债券代码：110076 | 债券简称：华海转债 | | | | 重要内容提示： 被担保人名称：湖北赛奥生物制药有限公司（以下简称"湖北赛奥"）， 为浙江华海药业股份有限公司（以下简称"公司"或"华海药业"）下属控股子公 司； 本次担保金额及已实际为其提供的担保余额：本次公司为下属子公司湖北 赛奥提供担保金额不超过 1.5 亿元。截止本公告披露日，公司已实际为其提供的 担保余额为 0 元（不包括本次担保）； 一、 担保情况概述 （一）本次担保基本情况 公司于 2023 年 12 月 27 日召开第八届董事会第二十二次临时会议，会议审议 通过了《关于公司为下属子公司提供担保的议案》，董事会同意公司为下属控股子 公司湖北赛奥向银行申请授信额度提供不超过人民币 1.5 亿元的信用担保，并授 权公司经营管理层或经营管理层转授权相关人士在上述担保额度内全权办理相关 手续，具体实施事宜无须再另行提交公司董事会审议。 具体内容详见公司于 2023 年 12 ...

Financial Performance - The company's operating revenue for Q1 2024 reached ¥2,498,671,124.15, representing a year-on-year increase of 21.36%[4] - Net profit attributable to shareholders was ¥270,842,789.22, reflecting a significant growth of 56.62% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥315,424,401.91, an increase of 67.29% year-on-year[4] - Basic and diluted earnings per share were both ¥0.19, up by 58.33% year-on-year[4] - Total operating revenue for Q1 2024 reached RMB 2,498,671,124.15, a 21.3% increase from RMB 2,058,913,113.43 in Q1 2023[16] - Net profit for Q1 2024 was RMB 273,944,434.55, representing a 62.7% increase compared to RMB 168,505,392.26 in Q1 2023[17] - The company reported a total profit of RMB 371,845,376.74 for Q1 2024, compared to RMB 240,883,645.68 in Q1 2023, marking a 54.4% increase[17] - The total comprehensive income for Q1 2024 was CNY 262,178,448.31, compared to CNY 148,538,126.97 in Q1 2023[25] Cash Flow - The net cash flow from operating activities was ¥853,246,043.03, showing a remarkable increase of 128.18% compared to the previous year[4] - Cash flow from operating activities generated RMB 853,246,043.03, significantly higher than RMB 373,933,429.54 in Q1 2023[19] - The net cash flow from investing activities was -471,690,659.45 RMB, a decrease from -521,104,230.29 RMB year-over-year[20] - The company reported a net cash flow from financing activities of 1,093,031,459.41 RMB, significantly higher than 548,627,492.74 RMB in the same quarter last year[20] - The net increase in cash and cash equivalents for the quarter was 1,485,562,536.52 RMB, compared to 367,599,362.76 RMB in the previous year[20] - The company's cash inflow from financing activities totaled 1,838,330,000.00 RMB, compared to 1,440,000,000.00 RMB in the previous year[20] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥20,089,317,179.86, an increase of 8.01% from the end of the previous year[4] - The company's total assets amounted to ¥20,089,317,179.86, compared to ¥18,599,969,612.84 at the end of 2023, reflecting a growth of approximately 8.0%[15] - Total current assets reached ¥8,901,797,081.57, up from ¥7,621,698,796.25, indicating an increase of about 16.8%[13] - The total liabilities increased to ¥11,599,242,747.86 from ¥10,348,854,672.57, which is an increase of approximately 12.1%[15] - The total liabilities increased to 8,776,729,779.72 RMB from 7,713,638,601.41 RMB year-over-year[22] - The company's equity attributable to shareholders rose to ¥8,319,436,460.31 from ¥8,076,851,901.19, showing an increase of about 3.0%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 72,310, with the top ten shareholders holding significant stakes[8] - The company has not reported any new strategies or significant changes in shareholder structure during the reporting period[12] Expenses - Total operating costs increased to RMB 2,099,036,620.37, up 17.1% from RMB 1,791,603,923.39 in the same period last year[16] - Research and development expenses for Q1 2024 were RMB 213,856,487.20, slightly up from RMB 202,193,404.97 in Q1 2023[16] - Sales expenses increased to RMB 490,541,619.20, a rise of 42.4% from RMB 344,775,680.27 in the previous year[16] - The company reported a financial expense of CNY 20,187,931.25 in Q1 2024, significantly reduced from CNY 68,797,147.86 in Q1 2023[24] Inventory and Investments - The company reported a total inventory of ¥3,236,962,151.59, down from ¥3,432,132,350.93, indicating a decrease of approximately 5.7%[13] - The company's inventory decreased to 2,330,768,586.18 RMB from 2,477,827,713.94 RMB year-over-year[21] - Long-term equity investments slightly decreased to ¥410,319,572.86 from ¥417,871,184.53, reflecting a decline of about 1.3%[14] - Long-term equity investments increased to 6,737,584,700.08 RMB from 6,586,268,218.76 RMB year-over-year[21] Market and Strategy - The sales team restructuring and market expansion efforts have led to improved market penetration and customer retention, contributing to revenue growth[7] - There were no new products or technologies announced in the current quarter[12]

Financial Performance - The company achieved operating revenue of CNY 8,308,719,758.46 in 2023, a year-on-year increase of 0.52%[19]. - The net profit attributable to shareholders was CNY 830,466,003.18, representing a decline of 28.88% compared to the previous year[19]. - The net profit after deducting non-recurring gains and losses was CNY 888,522,218.59, down 25.96% year-on-year[19]. - The net cash flow from operating activities increased by 78.40% to CNY 2,217,021,274.88[19]. - The company's total assets at the end of 2023 were CNY 18,599,969,612.84, a 2.47% increase from the previous year[19]. - Basic earnings per share decreased by 29.63% to CNY 0.57 in 2023[20]. - The weighted average return on net assets was 10.64%, down 5.91 percentage points from the previous year[20]. - The company reported a total of CNY 2,101,155,202.27 in operating revenue for Q4 2023[22]. - The total revenue for the company reached CNY 8,249,178,955.91, with a year-on-year increase of 0.81%[63]. - The gross profit margin decreased by 1.99 percentage points compared to the previous year, primarily due to the impact of domestic procurement policies leading to lower prices[63]. - Revenue from finished drug sales amounted to CNY 4,931,569,375.42, reflecting a year-on-year increase of 4.46%[63]. - The revenue from technical services surged by 264.60% year-on-year, totaling CNY 122,163,764.93[63]. - Domestic revenue was CNY 4,036,320,572.33, showing a decline of 4.45% year-on-year[63]. - International revenue reached CNY 4,212,858,383.58, with a year-on-year increase of 6.42%[63]. Research and Development - The company is focusing on upgrading its R&D strategy and expanding its product categories to enhance market competitiveness[26]. - R&D investment accounted for 14.08% of revenue, with 15 new domestic formulation approvals and 20+ ongoing projects in biopharmaceuticals[30]. - The company has 20+ ongoing biopharmaceutical projects, with 11 entering clinical research stages, focusing on unmet clinical needs[30]. - The company is focusing on the development of innovative drugs in the fields of autoimmune diseases and oncology, with over 40 domestic and international invention patents applied and more than 20 projects currently under research[39]. - The company has a robust pipeline with several drugs at different stages of development, indicating a strong commitment to research and development[103]. - The company reported a total investment loss of 78,119,814.57 RMB for the period, with a fair value change loss of 46,198,316.37 RMB from its investment in Junshi Bioscience (688180) and 19,356,244.33 RMB from its investment in Amgen Pharmaceuticals (688373)[116]. - The company is actively involved in the research and development of pharmaceutical products, including the production of various monoclonal antibodies[123]. - The company has received FDA orphan drug designation for HB0034, indicating its potential significance in treating rare diseases[92]. Market Expansion and Strategy - The company is actively expanding its sales network in Belt and Road countries, aiming to capture more commercial opportunities[28]. - The company is committed to building a core competitive product pipeline by increasing the development of generic and first-generic drugs[130]. - The company aims to achieve sustainable growth by balancing internal growth and external expansion, enhancing its brand reputation and industry influence[128]. - The company plans to strengthen its innovation technology system and accelerate the pace of new product development, focusing on key research areas and aligning with international advanced levels[129]. - The company is focusing on enhancing its market presence through strategic expansions and product diversification[84]. - The company aims to enhance its global marketing system and create a strategic operational ecosystem focused on expanding its market share in both domestic and international markets[130]. Corporate Governance - The company has established a robust internal control management system in compliance with relevant laws and regulations[187]. - The company held three shareholder meetings during the reporting period, ensuring broad participation and adherence to legal requirements[148]. - The board of directors consists of nine members, including three independent directors, ensuring compliance with relevant laws and regulations[148]. - The company has implemented strict insider information management to protect shareholder rights[149]. - The company has conducted training for employees to enhance awareness of insider information confidentiality[149]. - The company has established a scientific performance evaluation system linked to employee compensation and promotions, enhancing talent retention and governance[148]. Environmental and Safety Compliance - The company has increased its investment in safety and environmental protection facilities to enhance compliance and risk prevention capabilities[142]. - The company has implemented a comprehensive environmental protection mechanism as a key pollutant discharge unit[190]. - The company achieved a total COD discharge limit of 8.194 tons and ammonia nitrogen of 0.41 tons, meeting regulatory standards in 2023[190]. - The company operates a total of 1 wastewater discharge outlet located in the northern area of the plant, along with 12 gas discharge outlets, of which 2 are under construction[194]. - The total nitrogen oxides emissions for Zhejiang Huahai Pharmaceutical Co., Ltd. are capped at 6.465 tons for 2023, with actual emissions within the permitted range[194]. Talent and Workforce - The company has a strong talent pool, including over 100 high-level talents with overseas backgrounds, supporting its R&D capabilities[57]. - The number of R&D personnel is 1,848, accounting for 22.48% of the total workforce[73]. - The company has 113 employees with a doctoral degree and 707 with a master's degree, indicating a strong educational background among its workforce[176]. - The company has established a comprehensive talent training mechanism to support its rapid development and enhance its competitive strength[33]. Shareholder Returns - The company plans to distribute a cash dividend of 2 RMB per 10 shares to all shareholders, based on the total share capital after deducting shares held in the repurchase account[4]. - The total cash dividend amount for 2022 was approximately 354.54 million CNY, representing 42.69% of the net profit attributable to ordinary shareholders[182]. - The company’s cash dividend for 2022 was 0.24 CNY per share, which was implemented on July 3, 2023[179]. - The company plans to distribute a cash dividend of 0.2 CNY per share for the 2023 fiscal year, pending shareholder approval[179].

| 股票简称：华海药业 | 股票代码：600521 | 公告编号：临 | 2024-033 | 号 | | --- | --- | --- | --- | --- | | 债券简称：华海转债 | 债券代码：110076 | | | | 浙江华海药业股份有限公司 浙江华海药业股份有限公司（以下简称"公司"）于近日收到国家药品监督管 理局（以下简称"国家药监局"）核准签发的白消安注射液的《药品注册证书》，现 将相关情况公告如下： 一、药品的基本情况 药品名称：白消安注射液 剂型：注射剂 规格：10ml：60mg 申请事项：药品注册（境内生产） 注册分类：化学药品 4 类 申请人：浙江华海药业股份有限公司 药品批准文号：国药准字 H20243505 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品符 合药品注册的有关要求，批准注册，发给药品注册证书。 二、药品其他相关情况 关于获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 白消安注射液适用于联合环磷酰胺，作为慢性髓性白血病同种异体的造 ...